CN104016976A - 盐酸鲁拉西酮晶型及其制备方法和用途 - Google Patents
盐酸鲁拉西酮晶型及其制备方法和用途 Download PDFInfo
- Publication number
- CN104016976A CN104016976A CN201310066819.3A CN201310066819A CN104016976A CN 104016976 A CN104016976 A CN 104016976A CN 201310066819 A CN201310066819 A CN 201310066819A CN 104016976 A CN104016976 A CN 104016976A
- Authority
- CN
- China
- Prior art keywords
- crystal formation
- lurasidone hcl
- preparation
- lurasidone
- hcl crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310066819.3A CN104016976A (zh) | 2013-03-01 | 2013-03-01 | 盐酸鲁拉西酮晶型及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310066819.3A CN104016976A (zh) | 2013-03-01 | 2013-03-01 | 盐酸鲁拉西酮晶型及其制备方法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104016976A true CN104016976A (zh) | 2014-09-03 |
Family
ID=51434025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310066819.3A Pending CN104016976A (zh) | 2013-03-01 | 2013-03-01 | 盐酸鲁拉西酮晶型及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104016976A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107163037A (zh) * | 2017-07-05 | 2017-09-15 | 中国药科大学 | 一种盐酸鲁拉西酮氨基酸的共无定形物 |
-
2013
- 2013-03-01 CN CN201310066819.3A patent/CN104016976A/zh active Pending
Non-Patent Citations (2)
Title |
---|
匿名: "Crystalline form of (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-1H-4,7-methanisoindole-1,3-dione hydrochloride", 《IP.COM》 * |
泰皮: "《含能材料》", 28 February 2009 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107163037A (zh) * | 2017-07-05 | 2017-09-15 | 中国药科大学 | 一种盐酸鲁拉西酮氨基酸的共无定形物 |
CN107163037B (zh) * | 2017-07-05 | 2020-04-21 | 中国药科大学 | 一种盐酸鲁拉西酮氨基酸的共无定形物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101891738B (zh) | 达沙替尼多晶型物及其制备方法和药用组合物 | |
CN102086195B (zh) | 达沙替尼多晶型物及其制备方法和药用组合物 | |
CN102325778A (zh) | 盐酸纳美芬二水合物 | |
AU2013330603B2 (en) | Monohydrate crystal of fimasartan potassium salt, method for preparing same, and pharmacological composition comprising same | |
CN104744445A (zh) | 一种酪氨酸激酶抑制剂的晶型 | |
CN104788438A (zh) | 恩格列净b晶型及其制备 | |
CN104230886A (zh) | 阿昔替尼新晶型 | |
CN104016976A (zh) | 盐酸鲁拉西酮晶型及其制备方法和用途 | |
CN105294649A (zh) | 一种Ceritinib化合物及其药物组合物 | |
CN103059013B (zh) | 达沙替尼一水合物的晶型及其制备方法 | |
TWI705065B (zh) | 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途 | |
CN102070558B (zh) | 非布索坦的新晶型及其制备方法 | |
CN102070605B (zh) | 甲磺酸伊马替尼多晶型物和药用组合物 | |
CN102250084A (zh) | 达沙替尼多晶型物及其制备方法和药用组合物 | |
CA2961819C (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
WO2021000687A1 (zh) | Pac-1晶型的制备方法 | |
US9365559B2 (en) | Crystal form of Dabrafenib and preparation method of use thereof | |
CN105777651A (zh) | 聚腺苷酸二磷酸核糖转移酶抑制剂的晶型及其制备方法和医药用途 | |
CN103145731B (zh) | 奥氮平晶型及其制备方法和用途 | |
CN105294650A (zh) | 一种Ceritinib化合物及其药物组合物 | |
CN105017142A (zh) | 烟酰胺类衍生物的甲磺酸盐b晶型及其制备方法和应用 | |
CN104788435A (zh) | 一种蛋白酪氨酸激酶抑制剂的二苯磺酸盐的i型结晶 | |
CN100338038C (zh) | 阿立派唑的新晶型及其制备方法 | |
CN111848580B (zh) | 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用 | |
WO2023143427A1 (zh) | Arv-110的晶型及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
CB02 | Change of applicant information |
Address after: 222006 Jiangsu province Lianyungang Kaitai Dapu Road Industrial Area Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO., LTD. Address before: 222006 Jiangsu province Lianyungang Kaitai Dapu Road Industrial Area Applicant before: Jiangsu Hansoh Pharmaceutical Group Lianyungang Hongchuang Medical Co., Ltd. |
|
COR | Change of bibliographic data | ||
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160311 Address after: 222047 Lianyungang economic and Technological Development Zone, Jiangsu Applicant after: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO., LTD. Address before: 222006 Jiangsu province Lianyungang Kaitai Dapu Road Industrial Area Applicant before: JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO., LTD. |
|
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140903 |
|
RJ01 | Rejection of invention patent application after publication |